- NSCLC (Non-Small Cell Lung Cancer) and kidney tumor in the elderly patient with response to chemoimmunotherapy2021 | First Faculty of Medicine
- Developmental trends and treatment of non-small cell lung cancer2012 | Second Faculty of Medicine
- Studie IMpower110 a její výsledky2021 | First Faculty of Medicine
- Radiotherapy in non-small-cell lung cancer 20162016 | Publication without faculty affiliation
- Advances in NSCLC therapy - actual state of the art in biological targeted therapy2013 | Publication without faculty affiliation
- Osimertinib in treating advanced non-squamous non-small cell lung cancer2022 | First Faculty of Medicine
- When not even four ALK inhibitors are enough2020 | Faculty of Medicine in Pilsen
- Selected frequent special palliative procedures in NSCLC2020 | Faculty of Medicine in Pilsen
- KRAS mutations in non-small cell lung cancer and options of treatment2020 | First Faculty of Medicine
- Targeted therapy of non-small cell lung cancer2021 | Faculty of Medicine in Pilsen
- Case reports of patients with ALK-positive NSCLC and brain metastases2023 | First Faculty of Medicine
- Prognostic and predictive markers in non-small cell lung cancer (NSCLC) - 2nd part Summary2019 | Faculty of Medicine in Pilsen
- Treatment options for non-small cell lung stage III cancer2021 | Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Entrectinib v léčbě ROS1 pozitivního pokročilého nemalobuněčného plicního karcinomu a v léčbě solidních nádorů s NTRK fúzí2021 | First Faculty of Medicine
- Imunoterapie u nemalobuněčného plicního karcinomu2016 | First Faculty of Medicine
- Dual-energy CT in patients with NSCLC, possible benefit in detection of metastatic lymph nodes and monitoring therapy response2016 | Faculty of Medicine in Pilsen
- Results of the evaluation of osimertinib in previously non-treated patients with EGFR-mutated advanced NSCLC: FLAURA study2018 | First Faculty of Medicine
- Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib2019 | First Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Studie IMpower150 - analýza subpopulace EGFR pozitivních pacientů2021 | First Faculty of Medicine
- Nivolumab as second-line therapy for patients with advanced NSCLC (non-small cell lung cancer)2022 | First Faculty of Medicine
- Adjuvant chemotherapy in the treatment of non-small cell lung cancer2007 | First Faculty of Medicine
- The position of neoadjuvant chemotherapy within the treatment of non small cell lung cancer2007 | First Faculty of Medicine
- Ground-breaking ADAURA trial - osimertinib as adjuvant therapy of EGFR-mutated NSCLC2022 | First Faculty of Medicine
- Imunoonkologická léčba inhibitory kontrolních bodů2019 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Cemiplimab: monotherapy and combination therapy of NSCLC - analysis of locally advanced disease2023 | First Faculty of Medicine
- Současné možnosti léčby ALK-pozitivního NSCLC2021 | First Faculty of Medicine
- Nintedanib - interesting alternative forsecond line pulmonaty adenocarcinoma patients2016 | Faculty of Medicine in Pilsen
- Neo-/adjuvant immunotherapy and targeted therapy of non-small cell lung cancer2023 | Faculty of Medicine in Pilsen
- Immunotherapy and radiotherapy in locally advanced (metastatic) non small cell lung cancer2020 | First Faculty of Medicine, Faculty of Medicine in Pilsen